2024년 질량 분석 세계 시장 규모는 69억 3,000만 달러에 달할 것으로 예측됩니다. 2033년에는 117억 2,000만 달러에 달할 것으로 예상되며, 2025-2033년 CAGR은 5.72%를 보일 것으로 예측됩니다. 현재 북미가 시장을 독점하고 있으며, 2024년에는 약 41.7%의 큰 시장 점유율을 차지할 것으로 예측됩니다. 이 시장은 제약, 생명공학, 식품 안전 산업에서 정밀하고 신속한 분석 기법에 대한 수요로 인해 활성화되고 있습니다. 또한, 의약품 개발 및 발견에 대한 투자 증가와 만성 질환 증가로 인해 단백질체학, 대사체학, 임상 진단에 대한 질량 분석의 채택이 가속화되고 있습니다. 또한, 하이브리드 분광분석 기술과 자동화 기술의 향상으로 장비의 기능성이 향상되어 질량 분석 시장 점유율을 더욱 확대하고 있습니다.
이 시장은 고해상도 장비와 강화된 이온화 기술의 지속적인 발전이 큰 영향을 미치고 있으며, 그 결과 각 분야에서 더욱 광범위하게 활용되고 있습니다. 또한, 환경오염과 미량 검출에 대한 우려가 식품 검사 및 수질 모니터링으로 확대되고 있습니다. 2025년 1월에 발표된 조사에서 GC MS, LC MS/MS, 고해상도 하이브리드 시스템을 포함한 질량 분석이 물, 토양, 대기를 매트릭스로 하는 신흥 환경 오염 물질의 미량 수준 모니터링에 매우 중요한 역할을 하고 있음을 강조하고 있습니다. 수중 잔류 의약품의 검출 한계는 1.13-5.45 ng L-1로 낮으며, 휘발성 유기 화합물의 실시간 검출과 고해상도 플랫폼으로 가능한 비표적 스크리닝 기능을 강조합니다. 또한, 의약품 파이프라인의 확대와 바이오 의약품 연구의 급증으로 정밀한 분자 특성 평가가 필요해지면서 수요를 더욱 촉진하고 있습니다.
미국에서는 개인 맞춤형 의료와 유전자 연구에 대한 관심이 높아지면서 상세한 분자 프로파일링 도구에 대한 요구가 증가하면서 시장을 주도하고 있습니다. 또한, 새로운 시장 동향 중 하나는 연방 정부의 생물 의학 및 임상 연구에 대한 막대한 자금 지원으로 장비의 대폭적인 업그레이드가 유지되고 있다는 점입니다. 업계 보고서에 따르면, 미국 국립보건원(NIH)은 매년 470억 달러 이상을 투자하고 있으며, 건강, 의학, 행동학 연구에 대한 세계 최대 규모의 공공 자금 지원 기관으로 자리매김하고 있습니다. 또한, 식품 표시 및 잔류 농약에 대한 엄격한 규제는 농업 및 식품 검사 기관의 채용을 촉진하고 있습니다. 또한, 첨단 법의학 프로토콜의 개발과 국토 안보 대책의 강화로 인해 기관들은 정확한 감지 장비의 획득을 촉구하고 있습니다. 또한, 대사체학 및 리피도믹스 워크플로우에 질량 분석을 통합함으로써 연구의 깊이를 더할 수 있습니다. 또한, 대형 제조업체의 탄탄한 입지와 편리한 기술 지원은 전국 실험실에 대한 지속적인 투자를 촉진하고 있습니다.
기술 발전
지속적인 기술 발전이 시장 성장에 크게 기여하고 있습니다. 더 높은 감도, 더 나은 정확도, 더 빠른 처리 능력과 같은 최첨단 개선을 통해 이러한 장비는 현대 실험실에 필수적인 요소로 자리 잡았습니다. 또한, 기술의 발전으로 점점 더 복잡해지는 시료의 분석 등 질량 분석기기의 기능이 확대되고 있습니다. 또한, 고해상도 질량 분석 및 탠덤 질량 분석과 같이 전례 없는 수준의 디테일과 분석 깊이를 제공하는 최근의 기술 혁신이 시장 성장을 뒷받침하고 있습니다. 또한, 즉각적인 데이터 수집 및 해석을 가능하게 하는 실시간 모니터링 기능이 탑재되어 질량 분석 시장의 성장을 가속하고 있습니다. 또한, 장비의 소형화로 현장에서 분석에 사용할 수 있는 휴대용 유닛이 개발되어 시장 개척에 박차를 가하고 있습니다. 2025년 3월, 908 Devices는 우크라이나 보건부로부터 전후 환경 검사를 위한 유해물질 및 폭발물 감지용 MX908 휴대용 질량 분석기를 170만 달러에 수주하여 휴대용 솔루션에 대한 수요 증가를 강조하고 있습니다.
품질 관리에 대한 엄격한 규제 정책
의약품 및 식품 안전과 같은 산업에서 품질 관리에 대한 규제 요건이 시장 확대를 촉진하고 있습니다. 규제 당국의 엄격한 기준 도입으로 불순물 검출, 제품 품질 보증, 공정 검증에 있어 높은 정확도와 민감도를 가진 질량 분석을 신뢰하는 기업이 증가하고 있습니다. 또한, 질량 분석은 화합물이 순도 기준을 충족하고 극히 낮은 농도의 오염 물질이 검출되도록 보장합니다. 2025년 4월, 브루커는 RECIPE의 과반수 지분을 인수했습니다. RECIPE는 60명의 직원과 1,500만 달러의 매출을 자랑하는 뮌헨에 본사를 둔 임상용 MS 키트 공급업체로, 고처리량 '크롬 프리' ClinDART TDM 분석을 추진하고 있습니다. 또한, 농약, 독소 및 기타 오염 물질이 없는 것을 보장하기 위해 식품 산업에서 널리 사용되는 기술이 시장 성장을 가속하고 있습니다. 또한, 이러한 규제적 의무로 인해 질량 분석은 단순한 선택이 아닌 제품 개발 및 제조 공정의 품질 보증을 위해 필수적인 요소로 자리 잡았습니다.
개인 맞춤형 의료에 대한 관심 증가
개인 맞춤형 의료에 대한 관심이 높아지고 있는 것도 질량 분석 시장 전망에 긍정적인 영향을 미치는 중요한 요인입니다. 한 업계 보고서에 따르면, FDA는 300개 이상의 맞춤형 의약품을 승인했으며, 신약의 약 25%가 바이오마커 데이터와 관련이 있다고 합니다. 헬스케어는 환자 개개인에 맞추어지고 있으며, 이에 따라 상세한 분자 및 유전자 정보에 대한 수요가 증가하고 있습니다. 질량 분석은 바이오마커, 대사산물, 단백질을 분자 수준에서 분석할 수 있는 기능을 제공하며, 단백질체학 및 유전체학 연구에서 중요한 역할을 합니다. 이러한 결과는 개인의 건강 프로파일을 이해하고, 질병 감수성을 예측하고, 그에 따라 치료법을 조정하는 데 매우 중요합니다. 또한, 개인 맞춤형 의료의 부상으로 의료 제공업체와 연구 기관은 정확한 환자 맞춤형 데이터에 대한 수요에 대응하기 위해 조사 기술에 대한 투자를 확대하고 있습니다. 그 결과, 개인 맞춤형 의료에 대한 관심은 기존 시장에서의 질량 분석의 적용을 촉진할 뿐만 아니라 의학의 새로운 분야로의 진입을 개척하고 있습니다.
The global mass spectrometry market size was valued at USD 6.93 Billion in 2024. The market is projected to reach USD 11.72 Billion by 2033, exhibiting a CAGR of 5.72% during 2025-2033. North America currently dominates the market, holding a significant market share of around 41.7% in 2024. The market is fueled by the demand for precise and fast analytical methods in the pharmaceutical, biotechnology, and food safety industries. Moreover, increased investments in drug development and discovery, combined with the rising incidences of chronic diseases, are accelerating the adoption of mass spectrometry for proteomics, metabolomics, and clinical diagnostics. Furthermore, improvements in hybrid spectrometry technology and automation are improving instrument functionality, further augmenting the mass spectrometry market share.
The market is majorly influenced by the continuous advancements in high-resolution instrumentation and enhanced ionization techniques, which are encouraging wider use across sectors. Moreover, concerns over environmental contamination and trace-level detection have intensified deployment in food testing and water quality monitoring. A research study published in January 2025 highlights the pivotal role of mass spectrometry, including GC MS, LC MS/MS, and high resolution hybrid systems, in monitoring trace levels of emerging environmental contaminants across water, soil, and air matrices. It reports detection limits as low as 1.13-5.45 ng L-1 for pharmaceutical residues in water and emphasizes real time detection of volatile organic compounds and non targeted screening capabilities enabled by high resolution platforms. Also, expanding pharmaceutical pipelines and the surge in biopharmaceutical research require precise molecular characterization, further supporting demand.
In the United States, the market is driven by the growing emphasis on personalized medicine and genetic studies, which increases the requirement for detailed molecular profiling tools. Furthermore, one of the emerging mass spectrometry market trends is the substantial federal funding for biomedical and clinical research sustaining significant equipment upgrades. As per industry reports, the National Institutes of Health (NIH) invests over USD 47 Billion each year, making it the world's biggest public source of funding for research in health, medicine, and behavior. Besides, strict regulations for food labeling and pesticide residue drive adoption among agricultural and food testing labs. In addition, the development of advanced forensic protocols and heightened homeland security measures pushes agencies to acquire precise detection equipment. Also, integration of mass spectrometry into metabolomics and lipidomics workflows enhances research depth. Additionally, the robust presence of leading manufacturers and accessible technical support boosts continuous laboratory investments nationwide.
Technological Advancements
Continuous technological advancements are significantly contributing to the growth of the market. Cutting-edge improvements, such as higher sensitivity, better accuracy, and rapid throughput, are making these instruments indispensable in modern laboratories. Furthermore, technological progress is expanding the capabilities of mass spectrometry instruments to include the analysis of increasingly complex samples. Additionally, recent innovations like high-resolution mass spectrometry and tandem mass spectrometry that are providing unprecedented levels of detail and analytical depth are supporting the market growth. Moreover, the incorporation of real-time monitoring capabilities, allowing immediate data collection and interpretation, is strengthening the mass spectrometry market growth. In addition, the miniaturization of these devices is leading to the creation of portable units that can be employed for on-site analysis, thereby favoring the market development. As such, in March 2025, 908 Devices received a USD 1.7 Million order from Ukraine's Ministry of Health for MX908 handheld mass spectrometers to detect hazardous substances and explosives for post-war environmental testing, highlighting the growing demand for portable solutions.
Strict Regulatory Policies for Quality Control
Regulatory requirements for quality control in industries, such as pharmaceuticals and food safety, are propelling the market expansion. The introduction of stringent standards by regulatory agencies is prompting companies to rely on mass spectrometry for its high degree of accuracy and sensitivity in detecting impurities, ensuring product quality, and validating processes. In addition, mass spectrometry ensures that compounds meet purity standards and that contaminants are detected at extremely low concentrations. Accordingly, in April 2025, Bruker acquired a majority stake in RECIPE, a Munich-based clinical MS kit provider with 60 employees and USD 15 Million revenue, advancing high-throughput 'chrom-free' ClinDART TDM assays. Furthermore, the widespread technology utilization in the food industry to ensure the absence of pesticides, toxins, and other contaminants is favoring the market growth. Moreover, these regulatory compulsions make mass spectrometry not just an option but a necessity for quality assurance in product development and manufacturing processes.
Growing Focus on Personalized Medicine
The growing emphasis on personalized medicine is another pivotal factor positively impacting the mass spectrometry market outlook. An industry report noted that the FDA approved over 300 personalized medicines, with about 25% of new drugs linked to biomarker data, and personalized strategies now make up over 40% of major pharma pipelines. Healthcare is becoming increasingly tailored to individual patients, resulting in a higher demand for detailed molecular and genetic information. Mass spectrometry provides the capability to analyze biomarkers, metabolites, and proteins at a molecular level, thereby playing a significant role in proteomics and genomics research. These insights are crucial for understanding individual health profiles, predicting disease susceptibility, and tailoring treatments accordingly. Furthermore, the rise in personalized medicine is pushing healthcare providers and research institutions to invest in mass spectrometry technologies to keep up with the demand for precise, patient-specific data. As a result, the focus on personalized healthcare is not only boosting the application of mass spectrometry in existing markets but is also pioneering its entry into new avenues of medical science.
Triple quadrupole (tandem) leads the market with around 37.5% of market share in 2024.Triple quadrupole systems offer high sensitivity and selectivity, making them ideal for detecting low-abundance analytes in complex samples. Furthermore, they are versatile and can be applied to various fields, such as proteomics, metabolomics, pharmaceuticals, and environmental analysis. This multi-disciplinary application range contributes to their widespread adoption. Besides this, triple quadrupole mass spectrometers excel in quantitative measurements, as they provide excellent repeatability and accuracy, which are crucial in sectors like drug development and diagnostics. Additionally, these systems are often compatible with various ionization techniques and chromatography systems, allowing for broader applications and easier integration into existing workflows. Moreover, triple quadrupole meets or exceeds the stringent regulations and quality standards required in many industries, which makes them a safer investment for compliance-conscious organizations.
Pharmaceuticals lead the market in 2024. Pharmaceuticals are governed by strict regulatory standards. In line with this, mass spectrometry is invaluable for quality control and compliance, ensuring that pharmaceutical products meet these rigorous benchmarks. Furthermore, mass spectrometry is critical in the various stages of drug discovery, including target identification, screening, and pharmacokinetics. It provides accurate and precise data that aid researchers in the identification and quantification of compounds, thereby accelerating the time-to-market for new drugs. Besides this, mass spectrometry offers the high sensitivity and specificity required for proteomic and genomic studies, thereby driving its adoption in the pharmaceutical sector. Additionally, it is extensively used in metabolomics to identify and quantify metabolites, thus offering valuable insights into drug metabolism. Moreover, mass spectrometry is routinely used for quality control and batch-to-batch verification of raw materials, intermediates, and finished products.
In 2024, North America accounted for the largest market share of over 41.7%. North America hosts some of the world's leading research institutions and laboratories, which contributes to a high demand for mass spectrometry equipment for advanced research. Additionally, various government agencies are offering substantial grants and funding options for research and development (R&D) activities, including those that require mass spectrometry, thus fostering a favorable environment for market growth. Besides this, North America is the headquarters for numerous companies that are market leaders in the mass spectrometry segment. Moreover, the region is at the forefront of technological innovation in advanced mass spectrometry techniques like time-of-flight (TOF) and orbitrap. In addition to this, the presence of a robust healthcare system, coupled with the focus on precision medicine and diagnostics in the region, is further boosting the market growth.
United States Mass Spectrometry Market Analysis
In 2024, the United States holds a substantial share of around 87.50% of the mass spectrometry market share in North America. The market in the United States is primarily driven by strong investments in biomedical research, which are expanding applications in precision medicine and personalized healthcare. According to the World Health Organization (WHO), approximately 88% of all biomedical research grants, amounting to nearly USD 33 Billion, were awarded to organizations based in the United States. In line with this, the rapid integration of high-resolution mass spectrometry in clinical diagnostics, which facilitates the early detection of diseases and therapeutic drug monitoring, is driving market growth. The rise in biopharmaceutical manufacturing is further propelling demand for advanced analytical systems to ensure quality control and regulatory compliance. Similarly, increasing government fundings for environmental monitoring, which encourages the widespread deployment of pollutant and toxin analysis, is fostering market expansion. The rising focus on food safety testing for contaminants and residues is driving additional market appeal. Additionally, the expansion of forensic and crime laboratories is stimulating the use of portable and high-throughput mass spectrometry solutions. Apart from this, continuous innovations in hybrid and tandem systems, which reinforces U.S. leadership in analytical research capabilities, is expanding the market scope.
Europe Mass Spectrometry Market Analysis
The European market is experiencing growth due to strong investments in life sciences infrastructure, supported by national and EU-level funding initiatives. In accordance with this, the growing demand for advanced analytical techniques to meet stringent EU environmental regulations is driving market expansion. Similarly, rising investment in precision medicine and oncology programs, transforming the clinical diagnostics landscape, is expanding market reach. As such, in 2024, Berlin-based AI company Aignostics raised €31.4 million in Series B funding to enhance precision medicine through AI-driven pathology insights. The round was led by ATHOS, with investments from Mayo Clinic, HTGF, and other existing investors. The heightened need for food authenticity testing and contaminant traceability driving the deployment of high-resolution systems is supporting market demand. Additionally, the emerging trend of cross-border research collaborations, which encourages the adoption of interoperable, standardized analytical platforms, is stimulating market accessibility. The rapid expansion of biopharmaceutical pipelines and biologics manufacturing hubs is driving a significant increase in the market appeal. Besides this, Europe's expanding network of accredited testing facilities and the emphasis on laboratory automation are further providing an impetus to the regional market.
Asia Pacific Mass Spectrometry Market Analysis
The mass spectrometry market in the Asia Pacific is largely driven by rising government investments in precision medicine and genomic research. Furthermore, the growth of pharmaceutical manufacturing hubs in India and China, which drives demand for high-performance analytical instruments, is propelling market expansion. Similarly, increased collaborations between academic institutions and biotech companies, which foster innovation in biomarker discovery and proteomics, are strengthening market demand. The heightened adoption of stricter environmental monitoring standards is promoting the deployment of highly sensitive detection technologies. Additionally, the region's intensified focus on food safety testing is accelerating the use of mass spectrometry in the agro-food sector. Moreover, increasing funding for research and development is promoting the adoption of advanced mass spectrometry solutions in Asia Pacific healthcare and public health laboratories. Accordingly, in 2024, the National Natural Science Foundation of China (NSFC) and the U.S. NSF funded joint projects on infectious disease ecology and evolution, offering up to RMB 4.5 Million (about USD 630,000) per research project and RMB 1 Million (about USD 140,000) per exchange project, encouraging new international networks.
Latin America Mass Spectrometry Market Analysis
In Latin America, the market is growing due to increasing government investments in public health surveillance and advanced disease diagnostics. Similarly, the expansion of precision medicine programs is driving demand for high-resolution analytical tools to support the discovery of biomarkers and the development of targeted therapies. As such, in April 2025, MGI expanded its partnership with Brazil's Fiocruz to boost epidemiological surveillance and personalized medicine, equipping UNADIG's labs with advanced sequencers to process 2,000 genetic samples weekly and 29,000 clinical samples daily. The increasing emphasis on environmental monitoring and food safety regulations is driving the deployment of advanced mass spectrometry instruments for the detection of pollutants and quality control. Furthermore, expanding collaborations between local institutions and global pharmaceutical companies are driving technology transfer, advancing innovation, and broadening the market scope.
Middle East and Africa Mass Spectrometry Market Analysis
The mass spectrometry market in the Middle East and Africa is expanding due to increasing investments in healthcare infrastructure and advanced diagnostic capabilities across leading GCC nations. Furthermore, a heightened regulatory focus on food safety and environmental monitoring is driving the adoption of high-performance mass spectrometry in laboratories and testing centers. Similarly, collaborative research partnerships between regional universities and global analytical technology providers are supporting knowledge transfer and developing local expertise. Moreover, the region's growing pharmaceutical manufacturing sector is driving demand for precise analytical tools to ensure quality control, drug safety, and compliance with international standards, thereby providing an impetus to the market. Accordingly, in May 2025, Julphar announced a five-year investment plan of AED 300 Million (about USD 81 Million) to expand manufacturing, enhance technology, and encourage UAE pharmaceutical exports to over 40 global markets.
The competition in the market is intense, driven by continuous technological innovations and the growing requirement for accurate, dependable analytical solutions in a variety of industries. Firms in this market concentrate on creating hybrid platforms, miniaturized instruments, and user-friendly software interfaces to improve their competitive advantage. In addition, rigorous regulatory standards and increasing demand for sophisticated analytical capability across pharmaceutical development, food safety, and environmental testing drive ongoing investment in research and development (R&D). Besides, end users now place significant value on integrated systems that deliver accurate, complex analyses with minimal manual intervention, resulting in a greater emphasis on automation and ease of operation. Also, the demand for portable and high-throughput instruments is rising, driven by laboratories seeking to improve turnaround times and cost efficiency. According to the mass spectrometry market forecast, expanding applications in personalized medicine, proteomics, and metabolomics are expected to further accelerate the need for sophisticated mass spectrometry systems.